

Date: 14.02.2022

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 14th February, 2022.

Ref: Submission of Unaudited Financial Results for the quarter and nine months period ended on December 31, 2021 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulations 30 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board has at its meeting held on today i.e. 14th February, 2022 considered following matters:

1. Approved the Unaudited Financial Results of the Company for the quarter and nine months period ended December 31, 2021 along with the Limited Review Report of the Statutory Auditors.

Please find enclosed herewith Unaudited Financial Results along with Limited Review Report for the quarter and nine months period ended December 31, 2021.

2. Appointment of Mr. Jayesh Pushpavadan Jani as Chief Financial Officer (KMP) of the Company w.e.f 15th February, 2022.

The Meeting of the Board of Directors commenced at 11:30 a.m. and concluded at 02:00 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For Link Pharma Chem Limited



Bhushan Joshi
Company Secretary

Encl: As above.



**Link****Pharma Chem Ltd.**

ISO-9001 - 2015

ISO-14001 - 2015

REGISTERED OFFICE :

Plot No. 161/1, 162, G.I.D.C.,

Nandesari - 391340,

Dist. Baroda (Gujarat) (India)

Tel. (O) (0265) 2840281 / 2840282

E-Mail : linkpharmalimited@gmail.com

CIN: L24230 GJ 1984 PLC 007540

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2021

(in Rs. Lakhs)

Particulars	Quarter ended			Nine Months ended		Year ended
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Income :						
Revenue from operations	1,402.76	1,487.37	990.96	4,227.11	2,356.99	3,481.26
Other income	32.09	14.01	(0.43)	47.52	-	2.15
Total Income (A)	1,434.85	1,489.58	990.53	4,274.63	2,356.99	3,483.41
Expenses:						
Cost of materials consumed	978.55	1,056.23	600.49	2,913.04	1,116.37	1,793.26
Changes in inventories of finished goods and work-in-progress	20.58	(86.25)	(53.05)	(29.41)	(25.12)	(15.59)
Employee benefits expense	145.90	101.45	154.24	384.93	411.86	562.86
Finance costs	15.64	9.86	11.79	40.68	33.30	44.04
Depreciation and amortization expense	21.85	21.85	23.20	65.55	69.59	87.40
Other Expenses	153.54	332.74	203.36	670.27	619.72	843.59
Total expenses (B)	1,336.06	1,424.08	940.03	4,045.06	2,225.72	3,315.56
Profit before tax (C) = (A-B)	98.79	65.50	50.50	229.57	131.27	167.85
Tax expense:						
(1) Current tax	28.59	13.02	11.85	58.08	24.77	38.51
(2) MAT credit recognised	-	-	5.00	-	15.00	25.55
(3) Deferred tax	-	10.69	-	10.69	-1.37	(4.70)
Total tax expense (D)	28.59	23.71	16.85	68.77	38.40	59.36
Profit for the year (E) = (C-D)	70.20	41.79	33.65	160.80	92.87	108.49
Other Comprehensive Income (F)						
Items that will not be reclassified to profit or loss	-	3.00	-	3.00	3.00	6.06
Income tax effect on above	-	(0.60)	-	(0.60)	(0.60)	(1.79)
	-	2.40	-	2.40	2.40	4.27
Total comprehensive income for the year (G) = (E+F)	70.20	44.19	33.65	163.20	95.27	112.76
Paid up Equity Share capital of Rs 10 each	444.06	444.06	444.06	444.06	444.06	444.06
Earnings per equity share (Face value of Rs. 10) (Rs.)						
Basic and Diluted	1.58	0.94	0.76	3.62	2.09	2.44

Notes:

- These Financial Results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 14th February, 2022.
- The Company's operation fall under single segment namely "Chemicals" for the purpose of Indian Accounting standard (Ind As 108) on Segment Reporting.
- This statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Company confirms that its Statutory Auditors, M/s Sanjay Soni & Associates, have issued unmodified opinion on the financial results.

Place: Vadodara

Date: 14.02.2022

For and behalf of the Board of
Link Pharma Chem LimitedSatish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

S -16 C, India Bulls Mega Mall, Dinesh Mill Road, Near Jetalpur Flyover, Akota, Vadodara - 390 007.
(O) : 0265-2983872, (M) : 98254 83162, E-mail : sanjaysoni@gmail.com


Independent Auditors' Review Report on Unaudited Quarterly and year to date Financial Results date Result of Link Pharma Chem Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

**TO THE BOARD OF DIRECTORS OF
LINK PHARMA CHEM LIMITED**

- 1 We have reviewed the accompanying statement of Unaudited financial Results of **LINK PHARMA CHEM LTD.** ("the Company"), for the **Quarter and Nine months ended December 31, 2021** ("the statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulation"). This statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- 2 We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- 3 Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued there under and other recognised accounting practice and policies has not disclosed the information required to be disclosed in terms of regulation, read with the circular, including the manner in which it is to be disclosed, or the it contains any material misstatement.

For SANJAY SONI & ASSOCIATES
Chartered Accountants
FRN 113251W





CA Sanjay Soni
Partner

M. No. 040616

UDIN 22040616BXWPN9904

Place: Baroda

Date: 14.02.2022